American Century Companies Inc. Has $236.37 Million Stock Holdings in IQVIA Holdings Inc. $IQV

American Century Companies Inc. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 24.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,244,425 shares of the medical research company’s stock after selling 399,027 shares during the quarter. American Century Companies Inc.’s holdings in IQVIA were worth $236,366,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of IQV. Physician Wealth Advisors Inc. boosted its holdings in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. boosted its position in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of IQVIA in the 3rd quarter worth approximately $36,000. Asset Dedication LLC lifted its holdings in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares during the last quarter. Finally, Rothschild Investment LLC grew its stake in shares of IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IQV shares. Citigroup lowered their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. Jefferies Financial Group lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Barclays lowered their target price on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $231.80.

IQVIA Trading Up 5.0%

Shares of IQVIA stock opened at $179.09 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market cap of $30.39 billion, a price-to-earnings ratio of 22.79, a PEG ratio of 1.72 and a beta of 1.37. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The business has a 50-day moving average price of $212.19 and a 200-day moving average price of $208.00.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same period in the prior year, the company earned $3.12 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.